Literature DB >> 16217707

Increased levels of GFAP in the cerebrospinal fluid in three subtypes of genetically confirmed Alexander disease.

M Kyllerman1, L Rosengren, L-M Wiklund, E Holmberg.   

Abstract

GFAP levels in the CSF were highly elevated in three genetically confirmed cases of Alexander disease clinically conforming with infantile, early and late juvenile forms. No other CSF abnormalities were detected. Assay of CSF-GFAP may prove to be a rapid and cost-effective screening test in clinical variants of Alexander disease and an indicator of GFAP gene mutations.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16217707     DOI： 10.1055/s-2005-872876

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN： 0174-304X            Impact factor:   1.947


  17 in total

1.  A 2-month-old infant with vomiting, seizures, and progressive apathy.

Authors:  Alexander Larsen; Christine Martin; Sascha Meyer; Tilman Rohrer; Panagiotis Papanagiotou; Marjo van der Knaap; Ludwig Gortner
Journal:  Eur J Pediatr       Date:  2012-06       Impact factor: 3.183

2.  Adult-onset Alexander disease with an R66Q mutation in GFAP presented with severe vocal cord paralysis during sleep.

Authors:  Ayumi Hida; Hiroyuki Ishiura; Noritoshi Arai; Hisayo Fukuoka; Kanehiro Hasuo; Jun Goto; Yoshikazu Uesaka; Shoji Tsuji; Sousuke Takeuchi
Journal:  J Neurol       Date:  2012-05-23       Impact factor: 4.849

Review 3.  Young-onset dementia.

Authors:  Dulanji K Kuruppu; Brandy R Matthews
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

4.  Juvenile alexander disease: a case report.

Authors:  Halit Ozkaya; Abdullah Baris Akcan; Gokhan Aydemir; Mustafa Kul; Secil Aydinoz; Ferhan Karademir; Selami Suleymanoglu
Journal:  Eurasian J Med       Date:  2012-04

5.  Protein changes in immunodepleted cerebrospinal fluid from a transgenic mouse model of Alexander disease detected using mass spectrometry.

Authors:  Robert Cunningham; Paige Jany; Albee Messing; Lingjun Li
Journal:  J Proteome Res       Date:  2013-01-11       Impact factor: 4.466

Review 6.  Strategies for treatment in Alexander disease.

Authors:  Albee Messing; Christine M LaPash Daniels; Tracy L Hagemann
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

Review 7.  Dysfunctions of neuronal and glial intermediate filaments in disease.

Authors:  Ronald K H Liem; Albee Messing
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

8.  GFAP expression as an indicator of disease severity in mouse models of Alexander disease.

Authors:  Paige L Jany; Tracy L Hagemann; Albee Messing
Journal:  ASN Neuro       Date:  2013       Impact factor: 4.146

9.  GFAP mutations, age at onset, and clinical subtypes in Alexander disease.

Authors:  M Prust; J Wang; H Morizono; A Messing; M Brenner; E Gordon; T Hartka; A Sokohl; R Schiffmann; H Gordish-Dressman; R Albin; H Amartino; K Brockman; A Dinopoulos; M T Dotti; D Fain; R Fernandez; J Ferreira; J Fleming; D Gill; M Griebel; H Heilstedt; P Kaplan; D Lewis; M Nakagawa; R Pedersen; A Reddy; Y Sawaishi; M Schneider; E Sherr; Y Takiyama; K Wakabayashi; J R Gorospe; A Vanderver
Journal:  Neurology       Date:  2011-09-14       Impact factor: 11.800

Review 10.  Blood GFAP as an emerging biomarker in brain and spinal cord disorders.

Authors:  Ahmed Abdelhak; Matteo Foschi; Samir Abu-Rumeileh; John K Yue; Lucio D'Anna; Andre Huss; Patrick Oeckl; Albert C Ludolph; Jens Kuhle; Axel Petzold; Geoffrey T Manley; Ari J Green; Markus Otto; Hayrettin Tumani
Journal:  Nat Rev Neurol       Date:  2022-02-03       Impact factor: 44.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.